A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood

被引：210

作者：

Blennow K. ^{[1
,2
]}

机构：

[1] Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Mölndal

[2] Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal

来源：

Neurology and Therapy | 2017年 / 6卷 / Suppl 1期

关键词：

Alzheimer’s disease; Biomarkers; Cerebrospinal fluid; Neurofilament light; Neurogranin; Tau protein; β-Amyloid;

D O I：

10.1007/s40120-017-0073-9

中图分类号：

学科分类号：

摘要：

A set of core cerebrospinal fluid (CSF) biomarkers for Alzheimer’s disease (AD) includes total tau (T-tau), phosphorylated tau (P-tau) and β-amyloid 42 (Aβ42). These biomarkers reflect some of the key aspects of AD pathophysiology, including neuronal degeneration, tau phosphorylation with tangle formation, and Aβ aggregation with deposition of the peptide into plaques. The core AD CSF biomarkers have been validated clinically in numerous studies, and found to have a very high diagnostic performance to identify AD, both in the dementia and in the mild cognitive impairment stages of the disease. CSF Aβ42 has also been found to show very high concordance with amyloid PET to identify brain amyloid deposition. The synaptic protein neurogranin is a novel candidate CSF biomarker for AD and prodromal AD. High CSF neurogranin predicts future cognitive decline and seems to be more specific for AD than, for example, T-tau. Importantly, technical developments have given ultrasensitive measurement techniques that allow measurement of brain-specific proteins such as tau and neurofilament light (NFL) in blood samples. Both plasma tau and NFL are increased in AD, and a recent study showed that plasma NFL has a diagnostic performance comparable to the core AD CSF biomarkers, and predicted future cognitive decline. Future large longitudinal clinical studies are warranted to determine the potential for plasma tau and NFL to serve as first-in-line screening tools for neurodegeneration in primary care. © 2017, The Author(s).

引用

页码：15 / 24

页数：9

共 60 条

[1]

Blennow K., Hampel H., Weiner M., Zetterberg H., Cerebrospinal fluid and plasma biomarkers in Alzheimer disease, Nat Rev Neurol., 6, 3, pp. 131-144, (2010)

[2]

Beastall G.H., Watson I.D., Clinical Chemistry and Laboratory Medicine: an appreciation, Clin Chem Lab Med CCLM/FESCC., 51, 1, pp. 3-4, (2013)

[3]

Blennow K., Hampel H., CSF markers for incipient Alzheimer’s disease, Lancet Neurol, 2, 10, pp. 605-613, (2003)

[4]

Blennow K., Wallin A., Agren H., Spenger C., Siegfried J., Vanmechelen E., Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?, Mol Chem Neuropathol, 26, 3, pp. 231-245, (1995)

[5]

Vanmechelen E., Vanderstichele H., Davidsson P., Van Kerschaver E., Van Der Perre B., Sjogren M., Et al., Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization, Neurosci Lett, 285, 1, pp. 49-52, (2000)

[6]

Andreasen N., Minthon L., Clarberg A., Davidsson P., Gottfries J., Vanmechelen E., Et al., Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample, Neurology., 53, 7, pp. 1488-1494, (1999)

[7]

Olsson B., Lautner R., Andreasson U., Ohrfelt A., Portelius E., Bjerke M., Et al., CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis, Lancet Neurol., 15, 7, pp. 673-684, (2016)

[8]

Koopman K., Le Bastard N., Martin J.J., Nagels G., De Deyn P.P., Engelborghs S., Improved discrimination of autopsy-confirmed Alzheimer’s disease (AD) from non-AD dementias using CSF P-tau (181P), Neurochem Int, 55, 4, pp. 214-218, (2009)

[9]

Shaw L.M., Vanderstichele H., Knapik-Czajka M., Clark C.M., Aisen P.S., Petersen R.C., Et al., Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects, Ann Neurol, 65, 4, pp. 403-413, (2009)

[10]

Mattsson N., Andreasson U., Persson S., Arai H., Batish S.D., Bernardini S., Et al., The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers, Alzheimers Dement J Alzheimers Assoc, 7, 4, pp. 386-395, (2011)

← 1 2 3 4 5 6 →